IL99031A - Solid oral pharmaceutical compositions containing ifosfamide - Google Patents
Solid oral pharmaceutical compositions containing ifosfamideInfo
- Publication number
- IL99031A IL99031A IL9903191A IL9903191A IL99031A IL 99031 A IL99031 A IL 99031A IL 9903191 A IL9903191 A IL 9903191A IL 9903191 A IL9903191 A IL 9903191A IL 99031 A IL99031 A IL 99031A
- Authority
- IL
- Israel
- Prior art keywords
- weight
- ifosfamide
- parts
- capsules
- flow regulating
- Prior art date
Links
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 title claims description 60
- 229960001101 ifosfamide Drugs 0.000 title claims description 60
- 239000007787 solid Substances 0.000 title claims description 6
- 239000008203 oral pharmaceutical composition Substances 0.000 title description 2
- 239000002775 capsule Substances 0.000 claims description 40
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 12
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 12
- 239000001506 calcium phosphate Substances 0.000 claims description 11
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 11
- 239000002202 Polyethylene glycol Substances 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 10
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 10
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 10
- 239000013543 active substance Substances 0.000 claims description 9
- 238000011049 filling Methods 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 239000007884 disintegrant Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 235000010980 cellulose Nutrition 0.000 description 10
- 229920002678 cellulose Polymers 0.000 description 10
- 235000012222 talc Nutrition 0.000 description 10
- 239000000454 talc Substances 0.000 description 10
- 229910052623 talc Inorganic materials 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000001913 cellulose Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000001828 Gelatine Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 210000004051 gastric juice Anatomy 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 229920000151 polyglycol Polymers 0.000 description 5
- 239000010695 polyglycol Substances 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- ZZVDXRCAGGQFAK-UHFFFAOYSA-N 2h-oxazaphosphinine Chemical compound N1OC=CC=P1 ZZVDXRCAGGQFAK-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241001132374 Asta Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- BMQVRJOWNGSIEG-UHFFFAOYSA-L calcium;icosanoate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCCCC([O-])=O BMQVRJOWNGSIEG-UHFFFAOYSA-L 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- -1 chloroethylamino Chemical group 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- LDHBWEYLDHLIBQ-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide;hydrate Chemical compound O.[OH-].[O-2].[Fe+3] LDHBWEYLDHLIBQ-UHFFFAOYSA-M 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- FGCSIJPPCNCQJB-FAOVPRGRSA-M sodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;chloride Chemical compound [Na+].[Cl-].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O FGCSIJPPCNCQJB-FAOVPRGRSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4024683 | 1990-08-03 | ||
| SG181694A SG181694G (en) | 1990-08-03 | 1994-12-30 | Solid oral administration forms containing ifosfamide as active agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL99031A0 IL99031A0 (en) | 1992-07-15 |
| IL99031A true IL99031A (en) | 1996-09-04 |
Family
ID=25895607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9903191A IL99031A (en) | 1990-08-03 | 1991-08-01 | Solid oral pharmaceutical compositions containing ifosfamide |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US5158776A (cs) |
| EP (1) | EP0469440B1 (cs) |
| JP (2) | JP3061898B2 (cs) |
| KR (1) | KR0177170B1 (cs) |
| CN (1) | CN1046851C (cs) |
| AR (1) | AR247484A1 (cs) |
| AT (1) | ATE110261T1 (cs) |
| AU (2) | AU643309B2 (cs) |
| BG (1) | BG60900B1 (cs) |
| CA (1) | CA2048367C (cs) |
| CZ (1) | CZ280475B6 (cs) |
| DE (2) | DE4124481A1 (cs) |
| DK (1) | DK0469440T3 (cs) |
| EG (1) | EG19690A (cs) |
| ES (1) | ES2058999T3 (cs) |
| FI (1) | FI97951C (cs) |
| HK (1) | HK15695A (cs) |
| HR (1) | HRP920575B1 (cs) |
| HU (1) | HU206268B (cs) |
| IE (1) | IE66378B1 (cs) |
| IL (1) | IL99031A (cs) |
| LT (1) | LT3528B (cs) |
| LV (1) | LV10043B (cs) |
| MC (1) | MC2274A1 (cs) |
| MX (1) | MX9100441A (cs) |
| NO (1) | NO178252C (cs) |
| NZ (1) | NZ239222A (cs) |
| PT (1) | PT98532B (cs) |
| RO (1) | RO113611B1 (cs) |
| SG (1) | SG181694G (cs) |
| SI (1) | SI9111342B (cs) |
| SK (2) | SK279740B6 (cs) |
| ZA (1) | ZA916124B (cs) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996010996A1 (en) * | 1993-07-21 | 1996-04-18 | The University Of Kentucky Research Foundation | A multicompartment hard capsule with control release properties |
| ITFI970184A1 (it) * | 1997-07-30 | 1999-01-30 | Menarini Farma Ind | Composizioni farmaceutiche contenenti vitamina d e calcio,loro preparazione ed uso terapeutico |
| DE19733305A1 (de) * | 1997-08-01 | 1999-02-04 | Asta Medica Ag | Pharmazeutische Zusammensetzung enthaltend Ifosfamid und Carnitin |
| US6103297A (en) * | 1998-01-14 | 2000-08-15 | Matsushita Electronics Corporation | Method of manufacturing cathode-ray tube |
| DE19826517B4 (de) * | 1998-06-15 | 2006-03-23 | Baxter Healthcare S.A. | Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette |
| US20040253307A1 (en) * | 2003-02-04 | 2004-12-16 | Brian Hague | Sugar-free oral transmucosal solid dosage forms and uses thereof |
| DE102005008797A1 (de) * | 2005-02-25 | 2006-09-07 | Baxter International Inc., Deerfield | Trofosfamid-haltige Filmtabletten und Verfahren zu deren Herstellung |
| CN114010629A (zh) | 2014-01-06 | 2022-02-08 | 英国神盾Tx股份有限公司 | 三麦芽酚铁的剂量方案 |
| GB201418710D0 (en) | 2014-10-21 | 2014-12-03 | Iron Therapeutics Holdings Ag | Dosage regimen |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3987204A (en) | 1972-09-15 | 1976-10-19 | Sucrest Corporation | Direct compression vehicle |
| JPS5646807A (en) * | 1979-09-27 | 1981-04-28 | Japan Atom Energy Res Inst | Production of composition of complex gradually releasing physiologically active substance |
| DE3111428A1 (de) * | 1981-03-24 | 1982-10-07 | Asta-Werke Ag, Chemische Fabrik, 4800 Bielefeld | Oxazaphosphorin-4-thio-alkansulfonsaeuren und deren neutrale salze, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen |
| US4618692A (en) * | 1981-09-03 | 1986-10-21 | Asta-Werke Aktiengesellschaft | 4-carbamoyloxy-oxazaphosphorins |
| US5019385A (en) * | 1984-11-09 | 1991-05-28 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Novel lymphopine LK 2 and pharmaceutic compositions containing same |
| ATE66609T1 (de) * | 1986-07-11 | 1991-09-15 | Asta Pharma Ag | Loesungen von oxazaphosphorinen mit verbesserter stabilitaet und verfahren zu deren herstellung. |
| DE3804686A1 (de) * | 1988-02-15 | 1989-08-24 | Henkel Kgaa | Arzneimittel mit einer kombination von cytostatika bzw. hormontherapeutika und phosphonoderivaten |
-
1991
- 1991-07-15 RO RO148008A patent/RO113611B1/ro unknown
- 1991-07-24 DK DK91112368.5T patent/DK0469440T3/da active
- 1991-07-24 DE DE4124481A patent/DE4124481A1/de not_active Withdrawn
- 1991-07-24 AT AT91112368T patent/ATE110261T1/de not_active IP Right Cessation
- 1991-07-24 US US07/733,756 patent/US5158776A/en not_active Expired - Lifetime
- 1991-07-24 DE DE59102620T patent/DE59102620D1/de not_active Expired - Fee Related
- 1991-07-24 EP EP91112368A patent/EP0469440B1/de not_active Expired - Lifetime
- 1991-07-24 MC MC912206A patent/MC2274A1/xx unknown
- 1991-07-24 ES ES91112368T patent/ES2058999T3/es not_active Expired - Lifetime
- 1991-07-30 MX MX9100441A patent/MX9100441A/es unknown
- 1991-07-31 JP JP3191414A patent/JP3061898B2/ja not_active Expired - Fee Related
- 1991-08-01 NZ NZ239222A patent/NZ239222A/xx not_active IP Right Cessation
- 1991-08-01 EG EG46991A patent/EG19690A/xx active
- 1991-08-01 SI SI9111342A patent/SI9111342B/sl not_active IP Right Cessation
- 1991-08-01 BG BG94934A patent/BG60900B1/bg unknown
- 1991-08-01 PT PT98532A patent/PT98532B/pt not_active IP Right Cessation
- 1991-08-01 IL IL9903191A patent/IL99031A/en not_active IP Right Cessation
- 1991-08-02 IE IE277491A patent/IE66378B1/en not_active IP Right Cessation
- 1991-08-02 ZA ZA916124A patent/ZA916124B/xx unknown
- 1991-08-02 CA CA002048367A patent/CA2048367C/en not_active Expired - Lifetime
- 1991-08-02 AR AR91320329A patent/AR247484A1/es active
- 1991-08-02 KR KR1019910013365A patent/KR0177170B1/ko not_active Expired - Fee Related
- 1991-08-02 AU AU81589/91A patent/AU643309B2/en not_active Ceased
- 1991-08-02 HU HU912594A patent/HU206268B/hu not_active IP Right Cessation
- 1991-08-02 CZ CS912409A patent/CZ280475B6/cs not_active IP Right Cessation
- 1991-08-02 FI FI913710A patent/FI97951C/fi active
- 1991-08-02 NO NO913019A patent/NO178252C/no not_active IP Right Cessation
- 1991-08-02 SK SK2409-91A patent/SK279740B6/sk not_active IP Right Cessation
- 1991-08-02 CN CN91105271A patent/CN1046851C/zh not_active Expired - Fee Related
-
1992
- 1992-09-29 HR HRP-1342/91A patent/HRP920575B1/xx not_active IP Right Cessation
- 1992-10-27 LV LVP-92-172A patent/LV10043B/lv unknown
-
1993
- 1993-08-23 AU AU44836/93A patent/AU649184B2/en not_active Ceased
- 1993-09-03 LT LTIP921A patent/LT3528B/lt not_active IP Right Cessation
-
1994
- 1994-12-30 SG SG181694A patent/SG181694G/en unknown
-
1995
- 1995-02-06 HK HK15695A patent/HK15695A/xx not_active IP Right Cessation
-
1998
- 1998-04-27 SK SK543-98A patent/SK279739B6/sk not_active IP Right Cessation
-
2000
- 2000-01-14 JP JP2000006836A patent/JP3545300B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI113336B (fi) | Menetelmä tramadolisuolaa sisältävän lääkeaineen valmistamiseksi, jolla on viivästynyt vaikuttavan aineen vapautuminen | |
| US5273758A (en) | Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms | |
| EP0317878B1 (de) | Stabilisierte Arzneistoffe, Verfahren zu ihrer Herstellung sowie stabile Arzneizubereitungen | |
| HK1010447B (en) | Tramadol salt containing medicaments with sustained release of the active ingredient | |
| DE60224194T3 (de) | Arzneizusammensetzungen enthaltend terbinafin und deren verwendung | |
| HUP0203334A2 (hu) | Közvetlen kompresszióval előállított polimer tabletta magok | |
| CA2048367C (en) | Solid oral forms of application containing ifosfamide as active substance | |
| US20020143058A1 (en) | Process for preparing non-hygroscopic sodium valproate composition | |
| KR100315618B1 (ko) | 베타-페닐프로피오페논유도체의지연방출성미세정제 | |
| JP3884056B1 (ja) | 口腔内速崩錠の製造方法 | |
| JPH1192369A (ja) | 医薬品調製物、その製造方法及びシランセトロンの安定化のための酸性添加剤の使用 | |
| US20070160667A1 (en) | Controlled release formulation of divalproex sodium | |
| KR20200110396A (ko) | 갑상샘 호르몬 또는 이의 유사체를 제공하는 조성물 및 방법 | |
| JP3967767B1 (ja) | 口腔内速崩錠の製造方法 | |
| EP1815850A1 (en) | Controlled release formulation of divalproic acid and its derivatives | |
| WO2007081341A1 (en) | Controlled release formulation of divalproic acid and its derivatives | |
| JPH11513046A (ja) | カプトプリル錠剤 | |
| KR20190142464A (ko) | 콜린 알포세레이트 함유 약제학적 조성물 | |
| SK11072000A3 (sk) | Tiagabínové prostriedky s predĺženým uvoľňovaním so zníženými vedľajšími účinkami | |
| WO2025110967A1 (en) | A modified release tablet composition of brivaracetam | |
| TR2023015500A1 (tr) | Bri̇varasetam i̇çeren deği̇şti̇ri̇lmi̇ş salimli bi̇r tablet kompozi̇syonu | |
| HUE029193T2 (en) | Delayed release drug formulations of thiocolchicoside | |
| KR20050085386A (ko) | 불안증 치료 방법 및 조성물 | |
| HU215191B (hu) | Eljárás Levodopa és Carbidopa hatóanyag-kombinációt tartalmazó, szabályozott hatóanyag-leadású, központi dopaminhiányos állapotok kezeléséhez alkalmas orális gyógyszerkészítmény előállítására | |
| HK1071847A1 (zh) | 具有延長的活性成分釋放的劑型 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| RH | Patent void | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |